Amneal announces proposed refinancing of existing credit agreement, including private offering of senior secured notes due 2032

Bridgewater, n.j., july 21, 2025 (globe newswire) -- amneal pharmaceuticals, inc. (“amneal”) (nasdaq: amrx) announced that its subsidiary, amneal pharmaceuticals llc (the “issuer”), is seeking to borrow $1.800 billion aggregate principal amount of new seven-year term b loans (the “new term b loans”) under a new term loan facility (the “term loan facility”). the issuer has also launched an offering of $750 million aggregate principal amount of senior secured notes due 2032 (the “notes”) in a private offering.
AMRX Ratings Summary
AMRX Quant Ranking